What if you could design something that acts like an antibody, but cheaper, more stable, and made entirely with chemistry?
Two LACDR researchers, Sebastian Pomplun and Matthias Barz, teamed up to do just that. By merging peptide synthesis with polymer chemistry, they developed synthetic molecules that mimic the size, shape, and function of antibodies, without the cold storage, high production costs, or immune side effects.
These ‘bottlebrush-like’ nanoscale particles are tough, modular, and ready for next-gen therapies. The concept worked from the very first experiment. The potential? Faster drug development, better patient access, and new pathways for targeting disease.
Read the full story here.
Starting Friday, November 14 at 4:00 p.m., two temporary closures (in place for the duration of the Plesmanlaan project, until approximately Q3 2027) will be implemented for...
24 October 2025, Over the past 20 years, Dutch hospitals have filed 559 European patent applications. This emerges from a new study by the European Patent Office and Fraunhofer...
Leiden, 24 October 2025 at 3:03 PMResearchers at LUMC, together with colleagues from the University of Florida, have identified hundreds of proteins in the blood that provide...